- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01509053
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (ARRIVE- EU)
February 12, 2015 updated by: Otsuka Pharmaceutical Development & Commercialization, Inc.
Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting, Europe, Canada and Asia
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Nonadherence to antipsychotic medications remains a frequent cause of relapse among patients with schizophrenia, increasing hospitalization rates, hospitalization days, and hospitalization costs.
Among hospitalized adults, schizophrenia is the fourth most commonly diagnosed illness and has the seventh longest mean duration of hospital stay in the US.
Frequent relapses and hospitalization can affect quality of life in these patients.
Long-acting injections (intramuscular depot) antipsychotic medication is a means to treatment adherence and increased quality of life for patients with schizophrenia.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brugge, Belgium, 8310
-
Bruxelles, Belgium, 1160
-
Kortenberg, Belgium, 3070
-
Liège, Belgium, 4000
-
-
-
-
-
Lovech, Bulgaria, 5500
-
Novi Iskar, Bulgaria, 1282
-
Pazardjik, Bulgaria, 4400
-
Tzerova Koria, Bulgaria, 5047
-
-
-
-
British Columbia
-
Penticton, British Columbia, Canada, V2A 4M4
-
-
Ontario
-
Chatham, Ontario, Canada, N7M 5L9
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who are able to provide written informed consent. If the Institutional Review Board (IRB) requires consent by a legally acceptable representative in addition to the subject, all required consents must be obtained prior to any protocol-required procedure.
- Male and female subjects 18 to 65 years of age, inclusive
- Current diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria and a history of the illness for at least 1 year (12 months)
- Subjects who in the investigator's judgment would benefit from extended treatment with a long-acting injectable formulation
- Subjects who have at least 1 inpatient psychiatric hospitalization in the 2 years (24 months) prior to screening, but have been managed as outpatients for the 4 weeks prior entering the study
- Subjects must have been on oral antipsychotic treatment for the full 7 months prior to the screening phase Subjects who have shown response to previous antipsychotic treatment.
- Subjects who understand the nature of the trial and are able to follow the protocol requirements.
Exclusion Criteria:
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated), or have been incarcerated in the past 7 months for any reason must not be enrolled into this trial.
- Subjects who may require potent CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers during the trial.
- Any subject who requires or may need any other antipsychotic medications during the course of the trial, other than allowed rescue medication.
- Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones.
- Subjects with a history of hypersensitivity to antipsychotic agents.
- Subjects deemed intolerant of receiving injectable treatment.
- Subjects who have received electroconvulsive therapy within the last 7 months prior to screening.
- Subjects with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia as assessed by the investigator.
- Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
- Subjects requiring hospitalization for any psychiatric reason during the 4 weeks prior to signing the Informed Consent Form (ICF) or during the screening period.
- Subjects without at least 1 inpatient psychiatric hospitalization in the last 2 years (24 months) prior to screening.
- Subjects who have met DSM-IV-TR criteria for any significant substance use disorder within 3 months prior to screening.
- Subjects who are considered treatment-resistant to antipsychotic medication other than clozapine.
- Treatment with long-acting injectable antipsychotics in which the last dose was within 7 months prior to screening.
- Subjects who have not been treated with oral antipsychotics for 7 months prior to screening.
- Subjects who have a significant risk of committing suicide
- Subjects who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
- Sexually active males and females who will not commit to utilizing birth control during the trial and for up to 180 days following the trial.
- Abnormal laboratory or physical examination results indicating a condition which may interfere with the results of the study or pose a safety risk to the subject.
- Subjects who have previously enrolled in an aripiprazole IM depot clinical study or who have participated in any clinical trial with an investigational agent within the past 30 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aripiprazole IM depot injection
Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot.
In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days.
Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase.
Oral aripiprazole was available as rescue medication if necessary.
|
400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg. Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014.
Other Names:
Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Inpatient Psychiatric Hospitalization Rates
Time Frame: Retrospective period Months 4-6; Prospective period Months 4-6
|
The comparison of inpatient psychiatric hospitalization rates (proportion of patients with ≥1 inpatient psychiatric hospitalizations) between the retrospective period Months 4-6 (Weeks-12 to -24) while on oral standard of care antipsychotic treatment and the prospective period Phase B Months 4-6 (Weeks 12 to 24) after the switch to aripiprazole IM depot.
|
Retrospective period Months 4-6; Prospective period Months 4-6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
Time Frame: Baseline, Week 24
|
The PANSS consisted of 3 subscales with a total of 30 symptom constructs each rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms.
The Positive Subscale consisted of 7 positive symptom constructs with a possible subscale score of 7 to 49, the Negative Subscale consisted of 7 negative symptom constructs with a possible subscale score of 7 to 49 and the General Psychopathology Subscale consisted of 16 symptom constructs for a possible subscale score of 16 to 112.
The PANSS Total Score ranged from 30 (best) to 210 (worst; indicating more severe symptoms).
A Negative change from Baseline indicated improvement.
|
Baseline, Week 24
|
Change From Baseline in PANSS Positive and Negative Subscale Scores
Time Frame: Baseline, Week 24
|
The PANSS Positive Subscale consisted of 7 symptom constructs rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms.
The total score on the Positive Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms.
The PANSS Negative Subscale consisted of 7 symptom constructs rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms.
The total score on the Negative Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms.
A Negative change from Baseline indicated improvement.
|
Baseline, Week 24
|
Clinical Global Impression of Severity (CGI-S) Score
Time Frame: Baseline, Week 24
|
The severity of illness for each participant was rated using the CGI-S scale.
The investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?"
using an 8-point scale where 0=not assessed to 7=among the most extremely ill patients.
|
Baseline, Week 24
|
Clinical Global Impression of Improvement (CGI-I) Score
Time Frame: Baseline, Week 24
|
The participant's overall improvement was rated for each participant using the CGI-I scale.
The investigator rated the participant's total improvement by answering the following question: "Compared to his/her condition at baseline (prior to randomization), how much has the patient changed?" using an 8-point scale where 0=not assessed, 1=very much improved to 7=very much worse.
Lower scores indicated improvement.
|
Baseline, Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Tim Peters-Strickland, Otsuka Pharmaceutical Development & Commercialization, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
October 1, 2012
Study Completion (Actual)
October 1, 2012
Study Registration Dates
First Submitted
December 13, 2011
First Submitted That Met QC Criteria
January 9, 2012
First Posted (Estimate)
January 12, 2012
Study Record Updates
Last Update Posted (Estimate)
March 4, 2015
Last Update Submitted That Met QC Criteria
February 12, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
Other Study ID Numbers
- 31-11-284
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
Bradley LegaRecruiting
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Aripiprazole (Abilify®) IM Depot Injection
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Otsuka Beijing Research InstituteCompleted
-
Otsuka Beijing Research InstituteCompleted
-
Otsuka Beijing Research InstituteCompleted
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedBipolar I DisorderUnited States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States, Argentina, Bulgaria, India, Malaysia, Mexico, Philippines, Romania, Russian Federation, Serbia, Slovakia, Taiwan